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RISK OF THROMBOEMBOLISM IN PATIENTS DEVELOPING CRITICAL ILLNESS-ASSOCIATED ATRIAL 
FIBRILLATION 
 
Abstract 
Although common, the long-term significance of developing atrial fibrillation (AF) during a period of 
critical illness is unclear. We undertook a retrospective cohort analysis to assess the rate of 
thromboembolism (TE) in patients developing atrial fibrillation de novo during admission to our 
intensive care unit. 1955 patients were followed up (maximum follow-up 1276 days) for the 
occurrence of TE, of which 220 (11.3%) had developed AF or atrial flutter during their critical care 
admission.  There were 11 TE events among the patients with new AF (0.053 events per patient-
year), compared with 18 in the non-AF group (0.0059 events per patient-year). The unadjusted 
hazard ratio for TE in patients developing new AF compared with those not developing AF was 8.09 
(95% CI 3.08 – 17.19, p<0.001). In patients admitted to critical care, the development of AF appears 
to be associated with a significantly increased risk of subsequent thromboembolism. 
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Introduction 
Atrial fibrillation (AF) is prevalent in acute illness, representing the commonest arrhythmia in critical 
care settings,
1
 occurring in 10-15% of patients. The physiological insult of acute illness, altered 
sympathetic tone or inflammation
2,3
 have all been
 
proposed as triggers. The development of AF in 
this situation is a poor prognostic sign,
4
 particularly in severe sepsis, where it is associated with a 
two-fold increase in the risk of death over comparable patients who remain in sinus rhythm.
3
 Its 
prevalence, treatment and implications for mortality have therefore been extensively studied in this 
setting. 
 
In the general population AF confers significant risk of ischemic stroke,
5
 with clear international 
consensus about anticoagulant prophylaxis in all but the lowest-risk patients.
6
 The thromboembolic 
(TE) implications of AF arising during acute illness are less well studied
7
 and generally time-limited to 
the acute phase or hospital stay.
8,9
 Patients in the general population experiencing paroxysmal AF 
carry equivalent risk to those with persistent or permanent AF
10
 and paroxysmal AF is common in 
patients with apparently idiopathic stroke.
11,12
 Furthermore it is unclear if the TE risk of AF occurs 
due to the arrhythmia itself, or associated inflammatory or metabolic processes, such that the 
ephemeral nature of an arrhythmia may be falsely reassuring. 
 
Critical illness brings a plethora of intrinsic and iatrogenic stimuli for arrhythmogenesis, which are 
more transient than traditional risk factors, but limited evidence suggests important short- and 
longer-term risk nonetheless.
9
 This study therefore sought to assess the risk of thromboembolism 
following critical illness-associated AF arising in our intensive care unit (ICU). 
 
Methods 
The study was undertaken at a single, large, UK teaching hospital with tertiary specialties. The critical 
care unit comprises 13 general intensive care beds, nine for neurosurgery/trauma and additional 
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high-dependency capacity. A separate cardiothoracic ICU provides peri-operative care for cardiac 
surgery and was not included in this study. 
 
An electronic patient record system (Innovian, Dräger Medical, Germany) maintains real-time 
recording of vital statistics and note-keeping. Heart rhythm is manually inputted hourly and acute 
rhythm changes are flagged by nursing staff, with 12-lead electrocardiograms recorded electronically 
for physician review. Patients have electronic pro forma completed at admission and discharge. An 
independently populated electronic discharge record is used for all hospital admissions. A Picture 
Archiving and Communication System (PACS) contains all imaging studies and reports. Letters from 
outpatient clinic visits are recorded on central, computer databases. The patient administration 
system (PAS) records all hospital episodes including admissions, clinic attendances and deaths. 
 
The electronic records of all patients admitted to our ICU from September 2009 to September 2011 
were screened for the onset of AF or atrial flutter of at least 30 seconds duration during their 
admission. Exclusion criteria included patients with previously documented atrial arrhythmia, those 
known to have had heart valve surgery or with significant mitral valve disease,
13,14
 patients admitted 
to or discharged from ICU on therapeutic anticoagulation, and those <18 years old. Patients resident 
outside the hospital catchment area, where follow up could not be reliably conducted, were also 
excluded. Where patients were admitted to ICU more than once in the study period, the episode in 
which AF was first documented was used as the index admission. 
 
Baseline characteristics and episode details (including length of ICU stay, death and place of death if 
relevant, and illness severity described by Acute Physiology and Chronic Health Evaluation II 
(APACHE II) score
15
) were recorded. The occurrence of TE (stroke, transient ischaemic attack or 
systemic embolism) and presence of risk factors (heart failure, hypertension, age, diabetes mellitus, 
previous systemic TE, vascular disease, gender) were identified based on previously described 
definitions
14
 and a CHADS2VASc score was calculated. TE complications were only included in the 
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analysis if they occurred after both the onset of AF and admission to critical care, and were 
diagnosed by a consultant physician, or confirmed with appropriate imaging, or operative or post-
mortem examination. Where there was any doubt as to the occurrence of an event, this was 
included as an event in the non-AF group, but excluded in the AF group. 
 
Follow-up was conducted from the date of onset of AF, or the date of admission to the intensive 
care unit in patients who did not develop AF, to the earliest of: date of death, date of commencing 
therapeutic oral anticoagulation, or termination of study follow-up.  
 
Objectives and analyses 
The objective was to describe the rate of TE complications in patients developing new onset AF (or 
atrial flutter) in the context of acute illness or injury, in a general ICU, compared to those without AF. 
 
We used descriptive statistics to describe the baseline characteristics of the patient population. 
Categorical variables were expressed as numbers (percentages). Continuous variables were 
expressed as means (standard deviation) or medians (25
th
, 75
th
 percentiles). Event rates were 
described as both absolute values and per patient-year in both AF and non-AF groups. We used 
Kaplan-Meier estimates to show probability of TE in the two groups and Cox proportional hazards 
models to analyse time to TE. We used Kaplan-Meier estimates and a log-rank test to compare 
mortality between the two groups and Cox proportional hazards (PH) models to analyse time to 
death. For the main outcome; time to TE, as well as for mortality, unadjusted analysis was based on 
a Cox PH model including group (AF or non-AF) as a single predictor variable. The participant 
baseline characteristics age, gender, CHADS2VASc score and APACHE II score were included as 
covariates in separate Cox models and any found to be individually significantly associated with the 
outcome were included as confounders in an adjusted Cox PH model. Results are reported as 
estimated hazard ratios (HR), with 95% confidence intervals and p-values. All analyses were 
conducted using statistical software R (version 3.3.2).
16
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Ethical review 
The project was reviewed by our institutional review board and registered locally as a clinical audit. 
Further ethical review and the need for informed consent were waived. Identifiable patient data 
were utilised only to facilitate the cross referencing of data sources and records were otherwise 
anonymous. The study was conducted retrospectively, patients were not involved in its conduct and 
there was no impact on their care. 
 
Results 
From September 2009 to September 2011, there were 3625 admissions to critical care, comprising 
3078 individuals. After exclusions, 1955 patients were included in the analysis (Figure 1). 220 (11.3%) 
of these developed AF or atrial flutter during their critical care admission. The baseline 
characteristics of both groups are described in Table 1. 
 
Thromboembolic events 
There were 11 TEs in patients with new onset AF (0.053 events per patient-year; mean follow-up 344 
days) and 18 events in those without (0.0059 events per patient-year; mean follow-up 638 days). In 
the AF group, one patient suffered ischaemic bowel and the remainder had thrombotic strokes or 
transient ischaemic attacks. Two patients suffered watershed cerebral infarcts following 
subarachnoid haemorrhage and one during a carotid endarterectomy, all in the group without AF. 
 
At one year, Kaplan-Meier estimates of the probability of TE were 0.081 (95% CI 0.03 – 0.13) in the 
AF group, compared with 0.008 (95% CI 0.003 – 0.013) in the no AF group. At three years, these 
estimates were 0.097 (95% CI 0.037 – 0.152) and 0.015 (95% CI 0.008 – 0.023), respectively (Figure 
2).  
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Cox regression analysis showed strong evidence of an effect of new onset AF on time to occurrence 
of TE. Fitting a model with a single predictor variable for new onset AF, the estimated hazard ratio 
for TE in patients with new onset AF compared to those without was 8.09 (95% CI 3.08 – 17.19, 
p<0.001). The baseline characteristics CHADS2VASc score, APACHE II score and age were found to be 
individually associated with occurrence of TE and so an adjusted analysis consisted of a Cox 
regression model including a variable for new onset AF and for CHADS2VASc score, APACHE II score 
and age as possible confounding variables. This gave an estimated adjusted hazard ratio for TE (new 
onset AF/no new AF) 5.91 (95% CI 2.60 – 13.44, p<0.001). 
 
Mortality 
The mortality rate for the total follow up period was 61.8% (136/220) in the group with new AF 
compared to 33.9% (589/1735) in the group without. Analysis of time-to-death showed evidence of 
increased mortality among patients developing new AF, compared to those who did not (p<0.001, 
log-rank test). At one year, Kaplan-Meier estimates of survival were 0.45 (95% CI 0.38 – 0.52) in the 
AF group, compared with 0.72 (95% CI 0.70 – 0.74) in the no AF group. At three years, these 
estimates were 0.35 (95% CI 0.28 – 0.42) and 0.64 (95% CI 0.62 – 0.67), respectively. In-hospital 
mortality rates were 47.7% (105/220) and 19.3% (335/1735), respectively. Of those with AF, 80 died 
in ICU (36.4%) compared to 228 (13.1%) of those without. Three patients died in hospital on the 
same admission following a TE event; all had developed new onset AF. Cox regression analysis 
showed strong evidence of an effect of new onset AF on mortality. Fitting a model with a single 
predictor variable for new onset AF, the estimated hazard ratio for mortality in patients with new 
onset AF compared to those without was 2.47 (95% CI 2.05 – 2.97, p<0.001). The baseline 
characteristics CHADS2VASc, APACHE II, gender and age were found to be individually associated 
with mortality and so an adjusted analysis consisted of a Cox regression model including a variable 
for new onset AF and for CHADS2VASc, APACHE II, gender and age as possible confounding variables. 
This gave an estimated hazard ratio for mortality (new onset AF/no new AF) of 1.53 (95% CI 1.26 – 
1.87, p<0.001). 
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Discussion 
This study suggests that, rather than being simply an inevitable consequence of a physiological 
insult, the onset of AF or flutter in the acutely ill patient is associated with an increased risk of TE 
complications. This risk appears to persist and may exceed that seen in the general population.
14
 
 
The rate of in-hospital death in patients with AF was high in our study, a known association 
particularly in sepsis,
3,4,9
 and this finding is likely to reflect disease severity.
17
 
 
The association of AF with critical illness is well established
1
 and appears common to all acute illness 
– medical patients in intensive care develop AF around day one or two, similar to trauma
18,19
 and 
post-operative patients.
20
 The pathophysiology of AF and aetiology of thrombosis in this context are 
not completely understood.
21
 Inflammatory mediation has been proposed; acute-onset AF triggers 
platelet activation and monocyte interaction within minutes
22
 and platelets continue to express 
CD40 some weeks after successful cardioversion.
23
 Although the cause-effect relationship is 
debated, this might explain the high rates of AF and TE, although it is not clear whether 
inflammation, or some other pathology,
24
 persists to maintain TE risk over the duration we have 
observed. 
 
Limitations and other studies 
The major limitation of this study is its retrospective nature, with inherent difficulty verifying data 
accuracy. Although multiple sources were cross-referenced, potentially important data such as 
primary care records have not been examined, with the assumption that all thromboembolic 
complications would be referred for specialist assessment. We included patients with AF on the first 
day of their critical care admission if this had not been previously documented, presuming that the 
illness necessitating their admission also precipitated their AF, whereas it may have been present 
before. Pragmatically, these patients would usually be considered as having new onset AF and this 
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does not materially alter the clinical question therefore. The small numbers of events in either group 
limits multivariable analysis, although the large difference between groups and concordance with 
other, previous studies does provide some confidence. 
 
Anticoagulation may confound the risk assessment and follow-up of patients. Prophylaxis of venous 
thrombosis is standard practice for all critically ill patients without a clear contraindication and may 
have reduced the risk of in-hospital TE. Our omission of primary care data also risks failing to identify 
patients with AF who began anticoagulation in the community at a later date, although we would 
expect this to reduce the event rate in the AF group. Thus, if such patients were excluded this may 
actually increase the observed difference. Further limitations include the high exclusion rate for 
patients out of area, which was necessary to optimise the accuracy of follow-up, and the single 
centre nature of this analysis. 
 
Most prior assessment of this issue occurred via small, short-term studies.
7,8
 Recently however, one 
group has undertaken a number of large, population-based, epidemiological studies exploring the 
association of new-onset AF with sepsis. Walkey et al. used hospital claims data to demonstrate a 
2.6% risk of in-hospital stroke and 2.0% risk of readmission with stroke (non-significant trend) within 
the same year, highlighting the potential TE risk of new onset AF for the first time.
9
 A subsequent 
study of Medicare beneficiaries identified an increase in ischaemic stroke at 5 years from an 
admission with sepsis (5.3% in those with new-onset AF vs. 4.7% without; HR, 1.22; 95% CI, 1.15 – 
1.47)
25
. These studies acknowledge the limitations of claims data, particularly with regards to coding 
and the temporal association of triggers and events. This current study supports these previous 
analyses by providing, for the first time on this scale, patient-level analysis of all admissions through 
a critical care unit, incorporating history, physiological parameters, diagnoses and investigations. 
 
One further study has considered the predictive value of CHADS2 and CHADS2VASc scoring in the 
general critical care population.
26
 However, 25% of patients had a history of atrial arrhythmia pre-
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dating their critical illness and 9% experienced atrial tachycardia, which is not universally accepted as 
a risk factor for thromboembolism. In the six months of follow up there were 12 recorded 
‘thromboembolic’ complications, including two myocardial infarctions and four patients with 
documented left atrial appendage thrombus without embolic sequelae. Finally, the use of 
anticoagulation beyond the critical care stay was not considered. 
 
Future questions and research 
The implication for patients outside critical care environments is less clear. Although AF is commonly 
precipitated by acute illness the illness severity and subsequently high mortality rates in our patients 
may be different to the overall hospital population, and differences in the use and availability of 
critical care facilities may limit the applicability of these findings to other countries. There are a 
plethora of aetiological factors for both AF and TE associated with critical illness,
27
 including 
inflammation, septic emboli, fluid shifts, and cardiac and vasoactive pharmacotherapy, which may 
be relevant for the prevention and management of both AF and TE, in addition to pre-existing 
comorbidities.
27,28
 We have demonstrated association rather than causality, and further research is 
needed to establish whether the physiological insult of critical illness itself, or its management, 
present an independent risk of future TE. The true implication for all patients with critical illness will 
only be clarified with larger, prospective study.  
 
AF is common following cardiothoracic surgery with a stroke risk of 2-5%.
29,30
 One  systematic review 
found no AF-reduction strategy that significantly reduced the risk of stroke.
29
 As with the general 
population,
10
 aggressive rhythm control does not mitigate the risk of TE, although anticoagulation 
post-surgery may.
31
 Large epidemiological studies of the management of AF in critical care imply 
reticence to use anticoagulants in the acute phase due to the risk of haemorrhage
26,28
 and lack of 
short term efficacy.
32
 These findings reflect the general AF population, where longer term 
anticoagulation, and not rhythm control, is protective against TE. This will need to be carefully 
considered in future strategies for the reduction of TE in these patients. 
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Conclusion 
This study suggests that the onset of AF, or atrial flutter, during critical illness may be associated 
with longer term risk of systemic thromboembolism. Whether the occurrence of AF is causative, or a 
marker of increased risk, is not clear and similarly the role of mediators such as hypertension need 
further scrutiny, but the risk of TE appears to persist beyond the period of acute illness. Further, 
prospective, multi-centre analysis of this association is urgently required. 
 
What is already known about this subject? 
• AF is the commonest arrhythmia in critical care environments and its development during 
critical illness is associated with a worse prognosis 
• In the general population, the development of even paroxysmal AF is associated with an 
increased risk of systemic thromboembolism 
 
What does this study add? 
• The development of de novo AF during a period of critical illness is associated with an 
increased longer term risk of systemic thromboembolism 
 
How might this impact on clinical practice? 
• There is urgent need to establish the long term risk to patients who have experienced AF 
during an acute illness 
• Strategies for risk assessment and possibly long term anticoagulation need to be considered 
• Further consideration of the pathogenesis of thromboembolism in AF, and the relationship 
between cardiac arrhythmia and systemic processes, is warranted 
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Figures 
Figure 1: Patient inclusion and exclusion 
 
Figure 2: Kaplan-Meier estimates of the probability of thromboembolism in patients with new AF 
(red line), and in those without new AF (black line). Numbers accompanying the numbers at risk in 
parentheses are the cumulative number of censored observations. 
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Table 1 – Baseline characteristics of the study population 
 AF (N = 220) No AF (N = 1735) Total (N = 1955) 
Male, n (%) 137 (62.3) 901 (51.9) 1038 (53.1) 
Age, in years, median (25
th
, 75
th
 
percentile) 
73.0 (64.0, 80.0) 62.0 (47.0, 72.0) 63.0 (49.0, 73.0) 
Baseline risk factors, n (%) 
- Heart failure 
- Hypertension 
- Diabetes mellitus 
- Stroke or systemic embolism 
- Vascular disease 
 
20 (9.1) 
110 (50.0) 
35 (15.9) 
24 (10.9) 
64 (29.1) 
 
59 (3.4) 
390 (22.5) 
202 (11.6) 
86 (5.0) 
263 (15.2) 
 
79 (4.0) 
500 (25.6) 
237 (12.1) 
110 (5.6) 
327 (16.7) 
CHADSVASc score, mean (SD) 2.8 (1.6) 1.7 (1.4) 1.8 (1.5) 
APACHE score, mean (SD) 20.7 (7.0) 14.4 (7.2) 15.1 (7.4) 
AF = atrial fibrillation; APACHE = Acute Physiology and Chronic Health Evaluation II score; SD = standard 
deviation 
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